Last Week, Edwards Lifesciences Corporation (EW) Recorded A Gain Of $50.68

0
12

As of Wednesday close, Edwards Lifesciences Corporation’s (NYSE:EW) stock was up $1.6, moving up 2.15 percent to $75.91. The average number of shares traded per day over the past five days has been 4,108,740 shares. 3 times new highs have been achieved over the past 5 days, with a $0.88 gain in that time frame. In the last twenty days, the average volume was 7,291,775, while in the previous 50 days, it was 4,710,808.

Since last month, EW stock retreated -11.42%. Shares of the company fell to $67.13 on 11/08/22, the lowest level in the past month. A 52-week high of $131.73 was reached on 04/21/22 after having rallying from a 52-week low of $67.13. Since the beginning of this year, EW’s stock price has dropped by -41.40% or -$53.64, and marked a new high 3 times. However, the stock has declined by -42.37% since its 52-week high.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


EW stock investors should be aware that Edwards Lifesciences Corporation (EW) stock had its last reported insider trading activity 10 days ago on Nov 15. Chopra Daveen, the CVP, Surgical Structural Heart of the company, disposed of 4,000 shares for $74.18 on Nov 15. It resulted in a $296,720 divestment by the insider. MUSSALLEM MICHAEL A sold 19,875 shares at an average price of $74.15 on Nov 14. The insider now owns 157,353 shares following the transaction. On Nov 08, CVP,Strategy/Corp Development BOBO DONALD E JR sold 6,725 shares at $68.46 apiece. The transaction was valued at $460,393.

Valuation Metrics

Right now, Edwards Lifesciences Corporation (EW) has a P/E ratio of about 32.68. The stock’s beta is 1.03. Besides these, the trailing price-to-sales (P/S) ratio of 8.60, the price-to-book (PB) ratio of 7.57, and the price-to-cash flow ratio of 44.18 may also be considered.

Financial Health

In the three months ended September 29, Edwards Lifesciences Corporation’s quick ratio stood at 3.00, while its current ratio was 3.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.10, and the total debt-to-equity ratio was 0.10. On the profitability front, the trailing twelve-month gross margin is 78.90% percent. In the year ended September 29, operating margins totaled 31.20%. Based on annual data, EW earned $3.98 billion in gross profit and brought in $5.23 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 23.20%. Return on equity (ROE) for the past 12 months was 24.50%.

In Edwards Lifesciences Corporation’s quarter-end financial report for September 29, it reported total debt of $596.2 million against cash and short-term investments of $490.9 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. EW’s revenue rose 0.67% to $1.37 billion during the quarter, while net income inched up to $1.32 billion. While analysts expected Edwards Lifesciences Corporation to report $0.62 quarterly earnings, the actual figure was $0.61 per share, beating the consensus estimate by -1.60%. During the quarter, the company generated $437.8 million in EBITDA. The liabilities of Edwards Lifesciences Corporation were 2.42 billion at the end of its most recent quarter ended September 29, and its total debt was $682.8 million. The value of shareholders’ equity is $618.26 million.

Technical Picture

This quick technical analysis looks at Edwards Lifesciences Corporation’s (EW) price momentum. With a historical volatility rate of 30.10%, the RSI 9-day stood at 54.83% on 23 November.

With respect to its five-day moving average, the current Edwards Lifesciences Corporation price is up by +1.17% percent or $0.88. At present, EW shares trade -12.51% below its 20-day simple moving average and -22.52% percent below its 100-day simple moving average. However, the stock is currently trading approximately -19.35% below its SMA50 and -31.87% below its SMA200.

Stochastic coefficient K was 78.96% and Stochastic coefficient D was 76.29%, while ATR was 2.39. Given the Stochastic reading of 90.70% for the 14-day period, the RSI (14) reading has been calculated as 48.82%. As of today, the MACD Oscillator reading stands at 0.08, while the 14-day reading stands at 1.79.

Analyst Ratings

Edwards Lifesciences Corporation downgraded its rating on Edwards Lifesciences Corporation (NYSE: EW) to a Perform in a note to investors on October 28, 2022. The analysts firm previously had an Outperform rating on the stock.Edwards Lifesciences Corporation (EW) has been rated Overweight by analysts. According to 0 brokerage firms, EW is a sell, and 7 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 4 analysts rate Edwards Lifesciences Corporation stock as buy, with 16 recommending it as overweight.

With a median target price of $95.00, the current consensus forecast for the stock is $73.00 – $118.00. Based on these forecasts, analysts predict Edwards Lifesciences Corporation (EW) will achieve an average price target of $92.51.

LEAVE A REPLY

Please enter your comment!
Please enter your name here